Collectively, these preliminary findings highlight the significance of PPARγ epigenetic regulation and histone-modifying enzymes as possible pharmaceutical targets to treat NAFLD. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.